Aleafia Health — Q1 FY2023 Earnings Presentation
27 slides from Aleafia Health's earnings presentation, Aug 11, 2022
Slide 1: Q1 Fiscal Year 2023 Earnings Presentation
August 11, 2022 Q1 Fiscal Year 2023 Earnings Presentation AleafiaHealth.com
Slide 2: Disclaimer
Disclaimer FORWARD LOOKING INFORMATION Certain statements herein relating to the Company constitute “forward looking information”, within the meaning of applicable securities laws, including without limitation, statements regarding future estimates, business plans and/or objectives, sales programs,
Slide 3: Presenters
Presenters Executive Leadership Tricia Symmes Matt Sale Chief Executive Officer Chief Financial Officer 20+ years as a senior executive in the pharmaceutical, biotech, consumer packaged goods, and 16+ years of increasingly more senior finance executive experience. Deep capital markets, cannabis indu
Slide 4: Core Strategic Objectives
4 Core Strategic Objectives Continues to Demonstrate Growth and Leadership Across all Four Strategic Pillars on its Path to Profitability Top 10 Adult-Use Adjusted EBITDA Leadership in Medical Growing International Market Position Profitability • ~$27 million run-rate net revenue (1) • ~$11 million
Slide 5: Business Overview & Performance
Business Overview & Performance Q1 | FY2023 Earnings Presentation
Slide 6: Q1 FY2023 Highlights: Adult-Use Sales Channel
Q1 FY2023 Highlights: Adult-Use Sales Channel Robust Growth in Adult-Use Net Revenue Year over Year Driven by Flagship Everyday Brand….Divvy Adult-Use Revenue Divvy Entrenchment in Adult-Use Market $11.0 176% growth in revenue over the prior year 107% growth rate in net revenue over the prior year $
Slide 7: Aggressively Capturing Adult Use Share
Aggressively Capturing Adult Use Share Retail Sell Through Exceeds $20 Million per Quarter with Overall Market Share Approaching 2.5% in BC, AB, SK, and ON Pre-Rolls Q2 2021 Flower LP Rank 28 19 18 15 13 12 ü 3.2% Market Share ü 2.5% Market Share $25,000 3.00% in listed regions in listed regions ü 4
Slide 8: Approaching a Top Market Share Position Whilst Peers Cede Share
Approaching a Top 10 Market Share Position Whilst Many Peers Continue to Cede Market Share Amidst a Highly Competitive Environment Aleafia Continues to Scale its Adult-Use Business Market Share Position in Core Markets (1) QoQ Sell Through Growth Rate(2) ü Launched Sunday Market 9% House of Brands o
Slide 9: Target Addressable Market: Value Segment
Target Addressable Market: Value Segment Demonstrating Leadership Positions in the $750 Million Non-Premium Segment TAM of Value Segment (1) Progress Towards Top 10 Market Leadership Targets In Ontario (2) Flower + Pre-roll Vapes Concentrates Oils Topicals Divvy brand rapidly growing and demonstrati
Slide 10: Q1 FY2023 Highlights: Medical Sales Channel
Q1 FY2023 Highlights: Medical Sales Channel Growth in Underrepresented Markets and Patient Groups have Offset Industry Trends and Increased Market Share Medical Net Revenue Growth in Medical Patients & Market Share (2019 - 2021) 25,000 8.0% $2.8 7.0% $2.5 20,000 6.0% 5.0% 15,000 4.0% 10,000 3.0% 2.0
Slide 11: Q1 FY 2023 Highlights: International Sales Channel
Q1 FY 2023 Highlights: International Sales Channel Secured New European Partner $0.5 $0.5 • Enhances margins • Bulk flower sale agreement (no excise duties or finished goods packaging) • Price schedule tied to potency levels • Improves revenue and cash flow visibility • Two-year agreement with total
Slide 12: Maximizing Yield of Usable Flower Across Facilities
Maximizing Yield of Usable Flower Across Facilities to Support Continued Growth Diverse Cultivation Supply Spans Three Sites and Supports Sales Opportunities Domestically and Internationally Consistent Approach on Focus Across Three Cultivation Sites 1. Yield of Grade A / C flower 2. THC potency 3.
Slide 13: Financial Overview
Financial Overview Q1 | FY2023 Earnings Presentation
Slide 14: Multi-Pronged Growth Strategy Across Three High Value Pillars
Multi-Pronged Growth Strategy Across Three High Value Pillars Initiatives Underway to Drive Net Revenue Growth Across All Sales Channels for Branded Cannabis Product Portfolio Adult-Use Net Revenue Composition • Procure high quality usable flower Attain top 10 • Launch Divvy Buyer’s Club market shar
Slide 15: Q1 FY2023 Highlights
Q1 FY2023 Highlights Branded Cannabis Net Revenue Across Adult-use, Medical, and International Segments Drives Aleafia Health’s Path to Profitability Three months ended Key Highlights in the Quarter ($ millions) June 30, 2021 June 30, 2022 Net Revenue +13% Driven by Strong 31% Growth in Branded Cann
Slide 16: Strong Adult-Use Growth Rate Provides Catalyst for Valuation Re-Rate
Strong Adult-Use Growth Rate Provides Catalyst for Potential Valuation Re-Rate Top Quartile Growth Rates Provides Opportunity to Reduce Valuation Discount to Peers and Driver Shareholder Returns Sequential Quarterly Growth Rate in Retail Sell Through EV / 2023E Net Revenue (2) (Q2 CY2022 vs Q1 CY202
Slide 17: Transformation of the Business
Transformation of the Business Robust Growth in Revenue Partially Offset by Higher Excise Tax Burden Net Revenue Breakdown Net Revenue Breakdown (Q2 FY2022 June 30, 2021) (Q1 FY2023 June 30, 2022) Wholesale Wholesale Adult-Use International 17% 29% 30% 4% Adult-Use Medical 55% International Revenue
Slide 18: Current Capitalization
Current Capitalization Balance Sheet Transformation in Progress; Near-term Liquidity from Receivables Facility and No Near-term Refinancings Required March 31, 2022 June 30, 2022 Revolving Receivables Facility $0.5 $1.8 Liquidity to Drive Growth Term Loan due December 2023 $12.1 $12.1 Convertible De
Slide 19: Net Working Capital Optimization
Net Working Capital Optimization Net Working Capital being Optimized to Improve Liquidity and Optimize Returns on Capital Receivables Management Net Working Capital Optimization (1) • Receivables facility to fund A/R growth in sales to four provinces $40,000 120% Inventory Management $35,000 100% •
Slide 20: Significant Cost Rationalizations Continuing into FY2023
Significant Cost Rationalizations Continuing into FY2023 Current Adjusted SG&A Profile Flexible and Scalable to Facilitate Continued Revenue Growth Aggressive Cost Realizations Key Cost Containment Initiatives Underway Continuing to Reduce Adjusted SG&A Economics of Scale $14.0 230% Vendor consolida
Slide 21: Targeting Breakeven Adjusted EBITDA Profitability in Second Half of FY2023
Targeting Achieving Breakeven Adjusted EBITDA Profitability in the Second Half of FY2023 Current Adjusted SG&A Profile Flexible and Scalable to Facilitate Continued Revenue Growth Select Projects Underway to Drive Profitability Adjusted EBITDA Trending to Profitability ● Evolving product formats to
Slide 22: End Remarks
End Remarks Executive Leadership Q1 | FY2023 Earnings Presentation
Slide 23: Q&A
Q&A Q1 | FY2023 Earnings Presentation
Slide 24: Portfolio of Branded and International Products
Portfolio of Branded and International Products Branded Cannabis Portfolio Supports all Sales Channels Adult-Use Medical International • High frequency • Discerning cannabis • Unique occasion- • Omega / Melatonin • Broad appeal for • Oils, dried flower, • Dried Flower consumers, large aficionados ba
Slide 25: Retail Pull Through in Core Volume Categories
Retail Pull Through in Core Volume Categories Continued Growth Across the Two Largest Adult-use Categories Flower, Pre-Rolled and Vapes Over the Last 6 Quarters Dried Flower Pre-Rolled Vape Market Share +90% CQGR Market Share +69% CQGR Market Share +16% CQGR Since CY Q1 2021 Since CY Q1 2021 Since C
Slide 26: Non-IFRS Measures
Non-IFRS Measures EBITDA and Adjusted EBITDA: ($,M's) Q1 FY2022 Q2 FY2022 Q3 FY2022 Q4 FY2022 Q5 FY2022 Q1 FY2023 Net loss -11.2 -0.0 -82.9 -71.5 -4.2 -4.5 Add back: Depreciation and amortization 2.4 2.3 1.9 3.7 2.1 2.0 Interest expense, net 2.2 1.8 2.0 2.2 2.6 2.8 Income tax expense (recovery) - -
Slide 27: Non-IFRS Measures
Non-IFRS Measures Branded Cannabis Net Revenue: ($,M's) Q1 FY2022 Q2 FY2022 Q3 FY2022 Q4 FY2022 Q5 FY2022 Q1 FY2023 Wholesale Revenue 1.9 3.1 1.9 0.5 -1.0 2.1 Branded Cannabis Net Revenue 5.2 7.6 7.6 8.3 8.0 10.0 Total Net Revenue 7.1 10.7 9.6 8.8 7.0 12.0 Adjusted SG&A ($,M's) Q1 FY2022 Q2 FY2022 Q